T. Rowe Price Associates
CRBP icon

T. Rowe Price Associates’s Corbus Pharmaceuticals CRBP Stock Holding History

T. Rowe Price Associates’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$119K Hold
12,572
– – ﹤0.01% 2959
2025
Q4 		$103K Hold
12,572
– – ﹤0.01% 2941
2025
Q3 		$160K Buy
+12,572
New +$120K ﹤0.01% 2835
2025
Q1 		– Sell
-164,735
Closed -$1.95M – 3050
2024
Q4 		$1.95M Sell
164,735
-160,933
-49% -$2.7M ﹤0.01% 1663
2024
Q3 		$6.72M Buy
325,668
+23,482
+8% +$1.2M ﹤0.01% 1222
2024
Q2 		$13.7M Buy
302,186
+109,691
+57% +$4.61M ﹤0.01% 1049
2024
Q1 		$7.55M Buy
+192,495
New +$4.75M ﹤0.01% 1152
2023
Q1 		– Sell
-1,877
Closed -$6K – 2931
2022
Q4 		$6K Hold
1,877
– – ﹤0.01% 2912
2022
Q3 		$10K Hold
1,877
– – ﹤0.01% 2934
2022
Q2 		$14K Buy
1,877
+330
+21% +$3.19K ﹤0.01% 2940
2022
Q1 		$25K Buy
1,547
+553
+56% +$7.33K ﹤0.01% 2955
2021
Q4 		$18K Buy
994
+47
+5% +$1.27K ﹤0.01% 2964
2021
Q3 		$29K Hold
947
– – ﹤0.01% 2923
2021
Q2 		$52K Buy
947
+566
+149% +$31.4K ﹤0.01% 2897
2021
Q1 		$23K Buy
381
+19
+5% +$1.25K ﹤0.01% 2837
2020
Q4 		$14K Sell
362
-3,456
-91% -$129K ﹤0.01% 2660
2020
Q3 		$206K Hold
3,818
– – ﹤0.01% 2411
2020
Q2 		$961K Buy
3,818
+26
+0.7% +$5.25K ﹤0.01% 1799
2020
Q1 		$596K Buy
3,792
+97
+3% +$16.4K ﹤0.01% 1901
2019
Q4 		$605K Sell
3,695
-162
-4% -$23.9K ﹤0.01% 2088
2019
Q3 		$563K Buy
3,857
+663
+21% +$115K ﹤0.01% 2048
2019
Q2 		$664K Buy
3,194
+461
+17% +$98.7K ﹤0.01% 2007
2019
Q1 		$570K Sell
2,733
-283
-9% -$62.4K ﹤0.01% 2075
2018
Q4 		$528K Buy
3,016
+613
+26% +$122K ﹤0.01% 2055
2018
Q3 		$544K Buy
2,403
+10
+0.4% +$1.62K ﹤0.01% 2120
2018
Q2 		$363K Sell
2,393
-625
-21% -$114K ﹤0.01% 2279
2018
Q1 		$552K Buy
3,018
+757
+33% +$170K ﹤0.01% 2049
2017
Q4 		$482K Buy
2,261
+1,677
+287% +$359K ﹤0.01% 2105
2017
Q3 		$125K Buy
+584
New +$114K ﹤0.01% 2476

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates's CRBP Position: Q1 2026 in Review

T. Rowe Price Associates held its Corbus Pharmaceuticals (CRBP) position steady in Q1 2026 at 12,572 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #2959.

T. Rowe Price Associates first reported a position in CRBP in Q3 2017 and has held it in 29 quarters since. The position peaked at $13.7M in Q2 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • T. Rowe Price Associates held 12,572 shares of Corbus Pharmaceuticals worth $119K as of Q1 2026.
  • T. Rowe Price Associates left its Corbus Pharmaceuticals share count unchanged in Q1 2026.
  • Corbus Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2959 holding.
  • T. Rowe Price Associates first reported a position in Corbus Pharmaceuticals in Q3 2017 and has held it in 29 quarters since.
  • T. Rowe Price Associates's Corbus Pharmaceuticals position peaked at $13.7M in Q2 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.